

Organizatori:



Societatea Națională
de Oncologie Medicală
din România



Facultatea de Medicină
Universitatea Ovidius
Constanța

breast cancer
MDT
Multidisciplinary Team



Unified Perspectives:
Advancing
Breast Cancer
Treatment
Together

September 25-27, 2025
Ramada North Bucharest

Dear colleagues,

Welcome to the MDT Breast Conference “Unified Perspectives: Advancing Breast Cancer Treatment Together”, organised by the National Society of Medical Oncology in Romania (S.N.O.M.R.) with the support of the Faculty of Medicine, “Ovidius” University of Constanța. We are delighted to gather here in Bucharest, September 25–27, 2025, at Ramada North Hotel, for a complex scientific forum on breast cancer care!

Breast cancer treatment has long surpassed the boundaries of a single specialty. Today, therapeutic decisions are made within a complex ecosystem that includes oncologists, surgeons, radiologists, radiotherapists, pathologists, geneticists, and many other experts.

The program of the conference is designed to foster dialogue and collaboration among specialists from different fields, offering the opportunity to share expertise, explore innovative strategies, and better understand how multidisciplinary teams function in real-world settings. Our shared goal is to ensure that this approach becomes a practical reality in as many centers as possible, ultimately improving outcomes for patients with breast cancer.

Thank you for joining us in Bucharest to advance breast cancer treatment together!

President of S.N.O.M.R.:

Răzvan Ovidiu Curcă

*Vice President of S.N.O.M.R. and
Events Coordinator*

Laura Mazilu

The conference organizers would like to thank the following companies for their support in organizing the event:

PLATINUM



GOLD



SILVER



BRONZE



PARTNERS



Background Information

ORGANIZER:

National Society of Medical Oncology in Romania (S.N.O.M.R.)
Faculty of Medicine, "Ovidius" University, Constanța

CONFERENCE COORDINATORS:

Laura Mazilu, Răzvan Ovidiu Curcă

CONFERENCE VENUE:

Ramada North Hotel, Bucharest

Address: 44A Daniel Danielopolu Str.

Telephone no: +4021 233 5000

Web: <https://www.wyndhamhotels.com/ramada/bucharest-romania/ramada-hotel-and-suites-bucharest-north/overview>



OFFICIAL CONFERENCE WEBSITE:

<https://snomr.ro/breastcancer2025>

OFFICIAL LANGUAGES OF THE CONFERENCE:

Romanian and English

SCIENTIFIC ACCREDITATION:

The Opening Surgery Course: Breast Conservation in the Era of Precision Oncology: From Mastectomy to Reconstruction was accredited by the Romanian College of Physicians with **3 CME credits**.

The papers of the MDT Breast Conference "Unified Perspectives: Advancing Breast Cancer Treatment Together" were accredited by the Romanian College of Physicians with **14 CME credits**.

CONFERENCE MANAGEMENT:



Str. Anastasie Panu nr. 13,
Iași, România
Tel: +40.332.40.88.03
Web: www.eventernet.ro;
E-mail: contact@eventernet.ro



Str. Ioan Budai Deleanu nr. 8,
Sector 3, Bucharest, Romania
Tel: +40756279026
Web: www.ferca.ro
E-mail: suport@ferca.ro

CONFERENCE SECRETARIAT:

The Conference Secretariat will operate throughout the event and will be located in the lobby of the Ramada North Hotel Bucharest.

SECRETARIAT WORKING HOURS:

Thursday, September 25:	08:30 – 19:00
Friday, September 26:	08:30 – 18:00
Saturday, September 27:	08:30 – 13:00

HAND-OUTS AND ON-SITE REGISTRATION OF PARTICIPANTS:

Validation of participation and on-site registration of participants will be carried out at the Conference Secretariat.

BADGES:

The badges are issued to all registered conference participants and representatives of exhibiting companies. Access to the workshop rooms, the medical exhibition and any event-related area will be permitted only with the badge issued at the Secretariat.

PARTICIPATION CERTIFICATES:

Certificates of participation will be issued within 30 days after the end of the event, to the email address provided at registration.

SCIENTIFIC SECRETARIAT:

The Scientific Secretariat will operate within the Conference Secretariat during the same working hours. This is where all conference presentations are handed in and checked to ensure the smooth running of the proceedings.

ORAL PRESENTATIONS:

The materials for oral presentations must be sent by email to: contact@eventernet.ro no later than 3 hours before the presentation or handed in to the Secretariat of the conference one day before the presentation (for presentations delivered in the morning of the following day) or at the latest 3 hours before the presentation. Please make sure to clearly indicate the title of the presentation, the name of the session, the day and the time of the presentation.

The organizers do not assume responsibility for unverified presentations which have not been submitted to the Scientific Secretariat.

We also strongly recommend that the lecturers observe their allotted time in the program, lest the moderator should have to interrupt their presentation. The remaining time will be displayed on the screen in the conference room to allow for the appropriate use of the assigned time interval.

AUTHORS' RESPONSIBILITY:

Responsibility for the content of presentations and summaries lies exclusively with the authors.

TAKING PHOTOS, AUDIO&VIDEO RECORDING:

Photography and audio and/or video recording are prohibited in the conference rooms.

MEDICAL EXHIBITION:

The Medical Exhibition will run throughout the conference in the **DIAMOND 1 Hall** of the Ramada North Hotel Bucharest.

CONFERENCE ROOM:

The conference will be held in the **DIAMOND 2 Conference Room** of the Ramada North Hotel.

COFFEE BREAKS:

Coffee breaks will be organised in the Medical Exhibition area, at the times specified in the program.

LUNCH BREAKS:

The lunch breaks on the 25th, 26th and 27th of September will be held in **American Lounge Restaurant**, located on the same level as the conference room:

- Thursday, September 25: **12:30 - 13:30**
- Friday, September 26: **13:15 - 14:10**
- Saturday, September 27: **12:40 - 13:30**

DINNERS:

The organizers invite you to the following dinners:

- Thursday, September 25, **American Lounge** (Ramada North Hotel): **19:00**
- Friday, September 26, **Gourmet by Zaitoone** (Herastrau Park, 7-9 Nordului Street): **19:00 - 22:00**
Transfer by mini-buses will be provided from the Ramada North Hotel to the **Gourmet by Zaitoone**, at **18:45**.
The return transfer to the hotel will depart from the restaurant at **22:00**.

PROGRAM CHANGES:

Conference organizers reserve the right to make last minute changes in the program due to unforeseen circumstances.

International Lecturers

Apurna Jegannathen

MBBS MD, MRCP, FRCR

Clinical Oncologist
Nuffield Health – North Staffordshire Hospital, UK

Dr. Apurna Jegannathen is a leading consultant clinical oncologist based in University Hospital North Midlands NHS Trust Stoke-On-Trent, West Midlands, UK. She also sees patients at the highly regarded Nuffield Health - North Staffordshire Hospital and GenesisCare. She specialises in the treatment of all stages of breast cancer, lung cancer, carcinoma of unknown primary, radical radiotherapy, stereotactic ablative radiotherapy for lung and oligometastasis, chemotherapy, targeted therapy, and personalised precision therapy using next-generation sequencing (also known as genomic signatures). Dr. Jegannathen is the former clinical director for cancer services at the University Hospital of North Midlands (UHNM). She is currently the Chair of WM Lung EAG (expert advisory group) and the Chair of Grand Rounds for the UHNM NHS Trust.



Alongside her posts at the University Hospital of North Midlands and the Nuffield Health North Staffordshire Hospitals, Dr. Jegannathen holds the position of SABR lead and lung cancer lead at UHNM. She does charity works towards Holistic Care for Cancer patients.

Dr. Jegannathen previously completed training at the Christie Hospital in Manchester, the Royal Preston Hospital, the Royal Berkshire Hospital in Reading, and at the Queen Elizabeth University Hospital in Birmingham, as well as a period as visiting fellow at the renowned Princess Margaret Hospital in Toronto, Canada.

Alongside her clinical work, Dr. Jegannathen is actively involved in clinical research, and is principal investigator on many trials in lung and breast cancer, and has published numerous articles in peer-reviewed journals. She also devotes time to the teaching of undergraduate and postgraduate medical professionals. Along with the clinical research, Dr. Jegannathen shares multiple educational regional meetings on lung and breast cancer supported by pharmaceutical companies (Novartis, Roche, Pfizer, Astra Zeneca, Lilly, Otsuka, Eisai and Merck, Helsinn).

Meera Joshi

BSc, MBBS, PhD, FRCS

Oncoplastic Breast & Reconstructive Surgeon
Imperial College Healthcare NHS Trust, UK

Dr. Meera Joshi is an Oncoplastic Breast and Reconstructive Surgeon at Imperial College Healthcare NHS Trust. She graduated from Imperial College London in 2009 and went on to complete her PhD at the same institution.

Her clinical and academic career has been recognised through a number of prestigious fellowships, awards, and prizes:

- 2023 – Lynn Sage Scholar International Awardee, Chicago
- 2022 – First Place, National Oncoplastic TIG Fellowship
- 2022 – Clinical Entrepreneur Programme, NHS England
- 2019 – Rose Trees Essay Prize Runner-up, Royal College of Surgeons
- 2019 – First Place, London Surgical Symposium

She has also held the role of TIG Fellow Breast Trainee at Imperial College Healthcare NHS Trust, developing expertise in oncoplastic techniques and advancing academic breast surgery.



Evangelos Mallidis

MD

Consultant Oncoplastic Breast Surgeon
Ipswich Hospital - ESNEFT Foundation Trust

Evangelos Mallidis has been an NHS surgeon since 2016 and has been based in Ipswich since September 2017.

He completed his medical studies and specialised in general surgery in Greece. He moved to the UK in 2013 to specialise in breast surgery. He completed an oncoplastic breast fellowship at Frimley Park Hospital NHS in 2016 and obtained a diploma in “Oncoplastic Breast Surgery” at UEA (University of East Anglia). He has also worked as an NHS breast surgeon at Oxford University Hospitals and Kingston Hospital, as well as at Medway NHS Hospital and Castle Hill NHS Hospital (East Yorkshire).



Dr. Mallidis offers a wide range of services and treatments, including breast augmentation, breast reduction, breast uplift, lipofilling/lipomodelling, breast cancer care and One Stop Breast Clinic assessment.

Evangelos Mallidis is dedicated to teaching and training residents/junior doctors. He is an Associate Member of Higher Education (AFHEA Cambridge University) and responsible for students from the University of East Anglia and Cambridge University visiting the Ipswich Hospital Breast Team.

Mona B.E. Sulieman

MBBS, Fellowship (GS), MRSCed, MSc, FEBS, BRESO certified

**Consultant Oncoplastic and Reconstructive Breast Surgeon
Royal Cornwall Hospital, UK**

Miss Mona B.E. Sulieman is a highly accomplished Consultant Oncoplastic and Reconstructive Breast Surgeon and serves as the Breast Specialty Governance Lead at Royal Cornwall Hospital, UK. With a distinguished career in breast surgery, Miss Mona B.E. Sulieman specializes in combining oncological surgery with aesthetic reconstruction, providing patients with expert care in breast cancer management and reconstruction.



In addition to clinical practice, Miss Mona B.E. Sulieman is a dedicated Clinical Tutor at the University of Exeter Medical School (UEMS), where they actively contribute to the training and development of future medical professionals.

Miss Mona B.E. Sulieman earned an MBBS degree from Juba University, Sudan and later became a Member of the Royal College of Surgeons of Edinburgh (MRCSEd). Following a Fellowship in General Surgery in Sudan, Miss Mona B.E. Sulieman pursued advanced specialization, obtaining a Master's degree (MSc) in Oncoplastic Breast Surgery from the University of East Anglia, UK. Further enhancing their expertise, Miss Mona B.E. Sulieman completed a Fellowship in Oncoplastic Surgery with the European Board of Surgery (FEBS) and holds the prestigious BRESO Certification in European Breast Surgical Oncology.

With a comprehensive background in both clinical practice and education, Miss Mona B.E. Sulieman is recognized for their commitment to improving patient outcomes and advancing the field of oncoplastic breast surgery.

Miss Mona B.E. Sulieman is also a well known speaker in international conferences and webinars and faculty member in breast surgery courses.

Abbreviated Program

Thursday, September 25th, 2025

Surgery Course: Breast Conservation in the Era of Precision Oncology: From Mastectomy to Reconstruction

09:00	● Mastectomy
09:30	● Breast-conserving surgery
10:00	● Axillary Management – Other ideas/amendments welcomed
10:30	● Coffee Break
11:00	● Neo/adjuvant treatment
11:30	● Reconstruction
12:00	● Discussion
12:30	● Lunch

Program times are expressed in Romania local time

Thursday, September 25th, 2025

MDT Conference: Unified Perspectives: Advancing Breast Cancer Treatment Together

- 13:30 • Mammography and ultrasound in the evaluation of breast and axillary cancer
- 14:00 • The role of contrast mammography and MRI in breast cancer diagnosis
- 14:20 • The role of biomarkers in early breast cancer
- 14:40 • Considerations for systemic treatment in early breast cancer
- 15:00 • Multigene panels in neoadjuvant therapy – clinical practice
- 15:20 • Coffee Break
- 15:40 • Future directions in early ER-positive breast cancer – Treatment escalation & de-escalation
- 15:55 • Symposium by **AstraZeneca**
- 16:40 • Breast reconstruction: to implant or not to implant
- 16:55 • Axillary surgery – Evolving Approach
- 17:10 • Do Local Perforator flaps improve quality of life
- 17:25 • Multidisciplinary Surgery Session
- 19:00 • Dinner

Program times are expressed in Romania local time

Friday, September 26th, 2025

- **09:00** Current adjuvant radiotherapy of the axilla in breast cancer
- **09:15** Adjuvant radiotherapy after breast-conserving surgery
- **09:30** Modified fractionation debate
- **10:00** Symposium by **Roche**
- **10:20** Symposium by **Lilly**
- **11:20** Coffee Break
- **11:50** Optimizing treatment in premenopausal patients with lymph node involvement and low risk
- **12:05** Symposium by **Pfizer**
- **12:30** Symposium by **MSD**
- **13:15** Lunch
- **14:10** Adjuvant treatment in special populations (BRCA positive, ER-negative, lobular breast cancer)
- **14:25** Treatment of breast cancer in pregnant women
- **14:40** Onco Fertility
- **14:55** Complementary therapies – Lifestyle, diet
- **15:10** Symposium by **AstraZeneca**
- **15:55** Coffee Break
- **16:25** The value of multigene testing in adjuvant therapy – clinical practice
- **16:45** Discussion of clinical cases in a multidisciplinary session
- **19:00** Dinner

Saturday, September 27th, 2025

- 09:00 What makes mTNBC a special entity
- 09:15 Debate: Questions, answers, and practical insights in the treatment of TNBC
- 10:45 Coffee Break
- 11:05 Molecular MDT in BC
- 11:25 Neoadjuvant HT – a useful option
- 11:40 Symposium by **Swixx BioPharma**
- 11:55 Symposium by **Gilead**
- 12:10 Current developments in the treatment of HR+ metastatic breast cancer
- 12:25 Current developments in the treatment of HER2+ metastatic breast cancer
- 12:40 Lunch

Program times are expressed in Romania local time

PREGĂTĂ



SĂ ÎȘI TRANSFORME
CASA ÎN ACASĂ
FĂRĂ RECIDIVĂ




În EBC HR+, HER2- cu risc crescut^a și ganglioni limfatici pozitivi
**Numai Verzenios[®] amplifică beneficiul privind IDFS după 2 ani de
tratament, oferind pacienței protecție^b pe termen lung atunci când
aceasta are cea mai mare nevoie^{1,2}**




La pacientele cu EBC HR+

**Cel mai mare
risc de recidivă
este în primii
2 ani de la
tratamentul
primar³**



După 2 ani de tratament, Verzenios® oferă protecție pe termen lung¹

Beneficiul absolut privind IDFS continuă să se
amplifice după 5 ani de urmărire¹



Analiza la 5 ani a fost efectuată după o perioadă mediană de urmărire de 54 de luni.¹

**Protecție demonstrată – Verzenios® are cea mai lungă perioadă
de urmărire raportată vreodată pentru un IC DK4/6 în EBC^{1,2}**

¹EBC cu risc crescut în Cohorta 1 a fost definit prin pacienții care au prezentat ≥4 ganglioni limfatici pozitivi sau 1-3 ganglioni limfatici pozitivi și tumoră ≥5 cm, grad histologic 3 sau ambele.⁴

²În acest context, protecția este definită prin „reducerea riscului de recidivă în timp.”¹

Abrevieri:

ICDK4/6—inhibitor al kinazelor 4/6 dependente de ciclină; EBC=cancer mamar incipient (early breast cancer); HER2—status negativ pentru receptorul factorului de creștere epidermal uman 2 (human epidermal growth factor receptor 2); HR+=status pozitiv pentru receptori hormonal (hormone receptor); IDFS=supraviețuirea fără boală invazivă (invasive disease-free survival).

Referințe

1. Rastogi P et al. J Clin Oncol. 2024;42(9):987-93. 2. Hortobagyi GN et al. Ann Oncol. 2025;36(2):149-57. 3. Cheng L et al. Cancer Epidemiol Biomarkers Prev. 2012;21(5):800-9. 4. Johnston SRD et al. Lancet Oncol. 2023 ;24(1):77-90.

Acest material este destinat profesioniștilor din domeniul sănătății.

© 2025 Eli Lilly and Company.
Toate drepturile rezervate.

PP-AL-RO-1053

Pentru informații complete de
prescriere, vă rugăm să citiți
Rezumatul caracteristicilor
produsului Verzenios®, ultima
versune revizuită, scanând
codul QR alăturat.



Lilly
A MEDICINE COMPANY

Program

Thursday, September 25th

CHEIA MAI MULTOR POSSIBILITĂȚI PENTRU PACIENȚII CU TNBC

RAMBURSAT ÎN ROMÂNIA^{1,2}

KEYTRUDA® primul și singurul anti-PD-1 indicat la adulți în tratamentul TNBC local avansat sau în stadiu incipient, cu risc înalt de recurență, în asociere cu chimioterapie ca tratament neoadjuvant, iar apoi continuat în monoterapie ca tratament adjuvant după intervenția chirurgicală.^{3,4}

KEYTRUDA® este indicat în asociere cu chimioterapie pentru tratamentul cancerului mamar triplu negativ local recurent nerezecabil sau metastatic, la adulți ale căror tumori exprimă PD-L1 cu un CPS ≥ 10 și cărora nu li s-a administrat anterior chimioterapie pentru boala metastatică.³

Abrevieri: CPS, *combined positive score* (scor combinat pozitiv); PD-L1, *programmed death ligand 1* (ligandul 1 al apoptozei); TNBC, *triple-negative breast cancer* (cancer mamar triplu negativ).

Referințe: 1. Raport de evaluare a tehnologiilor medicale, publicat pe site-ul ANMDM, accesibil la https://www.anm.ro/_EVALUARE%20TEHNOLOGII%20MEDICALE/9835_2023_Keytruda_Pembrolizumabum.pdf, accesat la 20.09.2023. 2. Numărul de pacienți eligibili comunicați de comisiile de specialitate ale Ministerului Sănătății, pentru fiecare terapie în parte aferente medicamentelor pentru care s-a emis Decizie de includere condiționată în Lista în perioada decembrie 2022 - august 2023, pentru care deținătorii de autorizații de punere pe piață prin reprezentanți lor legal, în conformitate cu prevederile Ordinului MS/CNAS nr 735/976/2018 au depus la CNAS cererea prin care își exprimă disponibilitatea pentru începerea procesului de negociere a contractelor cost-volum/cost-volum - rezultat - situație actualizată 23 august 2023, accesibil aici <https://cnas.ro/wp-content/uploads/2023/08/numar-pacienti-eligibili-comunicati-de-MS-situatie-actualizata-23-august-2023.pdf>, accesat la 9.20.2023. 3. Rezumatul caracteristicilor produsului KEYTRUDA®, 31 ianuarie 2025. 4. NIMMDAR report on authorized medicines, <https://nomenclator.anm.ro/medicamente>, accesat 21 August 2023.

Pentru a raporta evenimente adverse, transmite reclamații de calitate sau solicita informații medicale legate de produsele MSD, vă rugăm să ne scrieți la adresa de e-mail dproc.romania@merck.com.

Acest material promoțional este destinat profesioniștilor din domeniul sănătății. Acest medicament se eliberează pe bază de prescripție medicală PR. Înainte de a prescrie KEYTRUDA®, vă să rugăm consultați Rezumatul caracteristicilor produsului, disponibil prin scanarea codului QR alăturat.

RO-OBR-00012 04/2025

Copyright ©2025 Merck & Co., Inc., Rahway, NJ, SUA și afiliații săi. Toate drepturile rezervate.

Pentru a vizualiza RCP
scanați codul QR



Merck Sharp & Dohme Romania SRL

Bulevardul Poligrafiei nr. 1A
Ana Tower, etaj 5, cod poștal 013704
Sector 1, București, România
Tel: +4 021 529 29 00; Fax: +4 021 318 52 36

Thursday, September 25th, 2025

**Surgery
Course:**

breast cancer
MDT
Multidisciplinary Team



Breast Conservation

in the Era of Precision Oncology:
From Mastectomy to Reconstruction

September 25, 2025

09⁰⁰ – 12³⁰

Ramada North, Bucharest

Coordinator: Victor Titirez

09:00 - 09:30

● **Mastectomy**

Speaker: Victor Titirez

09:30 - 10:00

● **Breast-conserving surgery**

Speaker: Meera Joshi

10:00 - 10:30

● **Axillary Management – Other ideas/amendments welcomed**

Speaker: Mona B.E. Sulieman

10:30 - 11:00

● **Coffee Break**

11:00 - 11:30

● **Neo/adjuvant treatment**

Speaker: Apurna Jegannathen

11:30 - 12:00

● **Reconstruction**

Speaker: Evangelos Mallidis

12:00 - 12:30

● **Discussion**

12:30 - 13:30

● **Lunch**

Program times are expressed in Romania local time

Thursday, September 25th, 2025

MDT Conference: Unified Perspectives: Advancing Breast Cancer Treatment Together

Moderator: Laura Mazilu

- 13:30 - 14:00** ● **Mammography and ultrasound in the evaluation of breast and axillary cancer**
Speaker: Miruna Ispas

- 14:00 - 14:20** ● **The role of contrast mammography and MRI in breast cancer diagnosis**
Speaker: Cezar Bețianu

- 14:20 - 14:40** ● **The role of biomarkers in early breast cancer**
Speaker: Mihai Stoicea

- 14:40 - 15:00** ● **Considerations for systemic treatment in early breast cancer**
Speaker: Apurna Jegannathen

- 15:00 - 15:20** ● **Multigene panels in neoadjuvant therapy – clinical practice**
Speaker: Silvia Rădulescu

- 15:20 - 15:40** ● **Coffee Break**

- 15:40 - 15:55** ● **Future directions in early ER-positive breast cancer – Treatment escalation & de-escalation**
Speaker: Silvia Ilie

- 15:55 - 16:40** ● **Symposium by AstraZeneca**
The Dialogue of Harmony: A Symphony of Survival in HER2-Positive Metastatic Breast Cancer
Speakers: Laura Mazilu, Răzvan Ovidiu Curcă

Program times are expressed in Romania local time

Thursday, September 25th, 2025

MDT Conference: Unified Perspectives: Advancing Breast Cancer Treatment Together

Moderator: Victor Titirez

16:40 - 16:55 ● **Breast reconstruction: to implant or not to implant**

Speaker: Meera Joshi

16:55 - 17:10 ● **Axillary surgery – Evolving Approach**

Speaker: Mona B.E. Sulieman

17:10 - 17:25 ● **Do Local Perforator flaps improve quality of life**

Speaker: Evangelos Mallidis

17:25 - 18:25 ● **Multidisciplinary Surgery Session**

Case presentation: Mădălina Iordache

*Panel: Cezar Bețianu, Apurna Jegannathen, Victor Titirez,
Meera Joshi, Mona B.E. Sulieman, Evangelos Mallidis,
Virgil Sivoglo*

19:00 ● **Dinner**

American Lounge, Ramada North Hotel

Program times are expressed in Romania local time

Program

Friday, September 26th



RESCRIEȚI VIITORUL LOR CU TUKYSA

În linia a 3-a de tratament
pentru MBC HER2+

INDICAȚIE TERAPEUTICĂ:

TUKYSA este indicat în asociere cu trastuzumab și capecitabina pentru tratamentul pacienților adulți cu cancer mamar HER2 pozitiv în stadiu avansat la nivel local sau metastatic cărora li s-au administrat cel puțin 2 scheme anterioare de tratament anti-HER2+.¹

HER, human epidermal growth factor receptor (receptorul factorului de creștere epidermal uman); MBC: metastatic breast cancer (cancer de sân metastatic).

Referințe: Rezumatul Caracteristicilor Produsului TUKYSA, iulie 2024.

▼ Acest medicament face obiectul unei monitorizări suplimentare. Raportarea reacțiilor adverse suspectate asociate cu acest medicament reprezintă o prioritate. Profesioniștii din domeniul sănătății sunt rugați să raporteze orice reacție adversă suspectată contactând Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România, e-mail: adr@anm.ro. Reacțiile adverse se pot raporta și la următoarea adresă: ROU.AEReporting@pfizer.com.



Pentru informații suplimentare privind acest medicament consultați Rezumatul Caracteristicilor Produsului (RCP) prin scanarea codului QR alăturat.

Medicament eliberat pe bază de prescripție medicală restrictivă: PR.

Acest material promoțional este destinat profesioniștilor din domeniul sănătății.

Pentru aspecte legate de promovarea medicamentului în România, vă rugăm să vă adresați reprezentantului local Swixx Biopharma SRL, e-mail: romania.info@swixxbiopharma.com; Tel.: +40 371 530 850.

Friday, September 26th, 2025

MDT Conference: Unified Perspectives: Advancing Breast Cancer Treatment Together

Moderator: Virgil Sivoglo

09:00 - 09:15 ● **Current adjuvant radiotherapy of the axilla in breast cancer**

Speaker: Ștefănel Vlad

09:15 - 09:30 ● **Adjuvant radiotherapy after breast-conserving surgery**

Speaker: Virgil Sivoglo

09:30 - 10:00 ● **Modified fractionation debate**

Case presentation: Victor Titirez

Panel: Virgil Sivoglo, Ștefănel Vlad

10:00 - 10:20 ● **Symposium by Roche**

A Transformational Progress in Breast Cancer – The Role of Kadcyla in Residual Disease

Speaker: Laura Mazilu

10:20 - 11:20 ● **Symposium by Lilly**

Redefining EBC care through patient centric approach

Speakers: Laura Mazilu, Fharat Raja, George Iancu, Virgil Sivoglo

11:20 - 11:50 ● **Coffee Break**

11:50 - 12:05 ● **Optimizing treatment in premenopausal patients with lymph node involvement and low risk**

Speaker: Daniela Zob

12:05 - 12:30 ● **Symposium by Pfizer**

Making the most of your CDK4/6i - key data and guidelines

Speaker: Mircea Dediu

12:30 - 13:15 ● **Symposium by MSD**

Keytruda in partnership with surgery: KN 522 and the One-Year Journey in early TNBC

Speakers: Victor Titirez, Bogdan Georgescu

13:15 - 14:10 ● **Lunch**

Friday, September 26th, 2025

MDT Conference: Unified Perspectives: Advancing Breast Cancer Treatment Together

Moderator: Amedeia Niță

- 14:10 - 14:25** ● **Adjuvant treatment in special populations (BRCA positive, ER-negative, lobular breast cancer)**
Speaker: Simona Volovăț
- 14:25 - 14:40** ● **Treatment of breast cancer in pregnant women**
Speaker: Amedeia Niță
- 14:40 - 14:55** ● **Onco Fertility**
Speaker: Mihaela Stana
- 14:55 - 15:10** ● **Complementary therapies – Lifestyle, diet**
Speaker: Bogdan Goga
- 15:10 - 15:55** ● **Symposium by AstraZeneca**
InnovateHER2 – From Pathological Insights to Advanced Therapeutic Strategies with Enhertu in HR+ mBC
Speakers: Amedeia Niță, Mihai Stoicea
- 15:55 - 16:25** ● **Coffee Break**
- 16:25 - 16:45** ● **The value of multigene testing in adjuvant therapy – clinical practice**
Speaker: Laurenția Galeș

Moderator: Raluca Pătru

- 16:45 - 17:45** ● **Discussion of clinical cases in a multidisciplinary session**
Case presentations: Laurenția Galeș, Raluca Pătru
Panel: Cezar Bețianu, Laurenția Galeș, Raluca Pătru, Virgil Sivoglo, Mihai Stoicea, Victor Titirez
- 19:00** ● **Dinner**

Gourmet by Zaitoone Restaurant (Herastrau Park, 7-9 Nordului Street):
Transfer provided at **18:45** from the Ramada North Hotel to the restaurant and at **22:00** back to the hotel


Împreună

consolidăm încrederea, pas cu pas!

– Partenerul medicilor. Sprijinul pacienților. –



Acest material este destinat exclusiv profesioniștilor din domeniul sănătății. Ziextenzo[®], Zarzio[®], Binocrit[®], Tabfyl[®] și Wyost[®] sunt medicamente și se eliberează pe bază de prescripție medicală restrictivă întocmită de medicul specialist: PR. Pentru informații complete de prescriere, consultați Rezumatul Caracteristicilor Produselor, disponibile scanând codul QR alăturat.



SANDOZ

Sandoz Pharmaceuticals S.R.L. - Calea Floreasca nr. 169A, clădirea A, et. 1, sect. 1, București, România • Tel.: +40 21 407 51 60 • Fax: +40 21 407 51 61 • mi.romania@sandoz.net
www.sandoz.ro • Farmacovigilență: adverse.event.romania@sandoz.net

MAG-WYO-09/25-01

Program

Saturday, September 27th

Saturday, September 27th, 2025

MDT Conference: Unified Perspectives: Advancing Breast Cancer Treatment Together

Moderators: Răzvan Ovidiu Curcă, Mircea Dediu

- 09:00 - 09:15** ● **What makes mTNBC a special entity**
Speaker: Mircea Dediu

- 09:15 - 10:45** ● **Debate: Questions, answers, and practical insights in the treatment of TNBC**
Chair: Mircea Dediu
Panel: Nicoleta Antone, Răzvan Ovidiu Curcă, Laura Mazilu, Răzvan Negreanu

- 10:45 - 11:05** ● **Coffee Break**

- 11:05 - 11:25** ● **Molecular MDT in BC**
Speaker: Nicoleta Antone

- 11:25 - 11:40** ● **Neoadjuvant HT – a useful option**
Speaker: Răzvan Ovidiu Curcă

- 11:40 - 11:55** ● **Symposium by Swixx BioPharma**
Current challenges and opportunities in the treatment of HER2+ metastatic breast cancer
Speaker: Laura Mazilu

- 11:55 - 12:10** ● **Symposium by Gilead**
Beyond the Challenge: Changes in the mTNBC journey
Speaker: Bogdan Georgescu

- 12:10 - 12:25** ● **Current developments in the treatment of HR+ metastatic breast cancer**
Speaker: Laura Mazilu

- 12:25 - 12:40** ● **Current developments in the treatment of HER2+ metastatic breast cancer**
Speaker: Răzvan Negreanu

- 12:40 - 13:30** ● **Lunch**

Program times are expressed in Romania local time

breast cancer
MDT
Multidisciplinary Team

snomr.ro/breastcancer2025



CONFERENCE MANAGEMENT:



Str. Anastasie Panu nr. 13,
Iași, România
Tel: +40.332.40.88.03
Web: www.eventernet.ro
E-mail: contact@eventernet.ro



Str. Ioan Budai Deleanu nr. 8,
Sector 3, Bucharest, Romania
Tel: +40756279026
Web: www.ferca.ro
E-mail: suport@ferca.ro